Coherus Oncology (CHRS) Operating Leases (2019 - 2026)

Coherus Oncology has disclosed Operating Leases across 8 years of filings, most recently posting $954000.0 for Q1 2026.

• Operating Leases for Q1 2026 came in at $954000.0, down 66.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $954000.0 (down 66.57% YoY), and the FY2025 annual result was $1.5 million, down 55.66% from the prior year.
• Operating Leases came in at $954000.0 for Q1 2026 at Coherus Oncology, down from $1.5 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $6.8 million in Q2 2022 to a low of $954000.0 in Q1 2026.
• The 5-year median for Operating Leases is $3.7 million (2024), against an average of $3.7 million.
• Across the five-year window, Operating Leases slumped 76.55% in 2023 and surged 160.24% in 2024, its largest moves.
• Coherus Oncology's Operating Leases stood at $5.0 million in 2022, then rose by 5.59% to $5.3 million in 2023, then tumbled by 38.33% to $3.3 million in 2024, then sank by 55.66% to $1.5 million in 2025, then sank by 34.52% to $954000.0 in 2026.
• The last three Operating Leases figures came in at $954000.0 (Q1 2026), $1.5 million (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.